German urologists develop online prostate biopsy tool:
This article was originally published in Clinica
Executive Summary
Urologists at Berlin's Charite Hospital have developed a computer programme aimed at determining whether a biopsy is necessary in the event of elevated PSA values. The programme, called "Risk estimation for prostate cancer", was devised on the basis of results from 944 patients who visited the hospital between 1996-2001. Free and total PSA values, as well as the patient's age, prostate volume and results of digital rectal examinations are fed into the programme. Additionally, doctors can include specificity and sensitivity values to determine the necessity of biopsy. The programme, which was developed by Carsten Stephan and Henning Cammann, does not yet recognise PSA values recorded when using the test system developed by Los Angeles, California-based firm Immulite, however the system may be adapted to cover these in the future. It can be accessed via the internet at: http://www.charite.de/ch/uro/schwerpunkte/pclass.html
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.